p62 anti-cancer DNA Vaccine - CureLab Oncology

Drug Profile

p62 anti-cancer DNA Vaccine - CureLab Oncology

Alternative Names: Elenagen

Latest Information Update: 13 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CureLab Oncology
  • Class Antineoplastics; Cancer vaccines; DNA vaccines
  • Mechanism of Action Autophagy stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 13 Apr 2017 CureLab Oncology plans phase II trials for Ovarian cancer and Breast cancer in USA (CureLab Oncology website, April 2017)
  • 13 Apr 2017 CureLab Oncology plans phase II trials for Ovarian cancer, Glioblastoma, Pancreatic cancer, and Stomach cancer (CureLab Oncology website, April 2017)
  • 13 Apr 2017 CureLab Oncology plans phase II trials for Breast cancer, Prostate cancer, Renal cancer, and Uterus cancer (Metastatic disease) (CureLab Oncology website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top